Position in GILD
as of Jun 30, 2026
· filed Jul 27, 2026
Position Value
$258,997
-$26,711 QoQ
Shares Held
2,050
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#1,763
of 2,266 holders
Holding Since
Jun 2020
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GILD Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Capital Investment Counsel, Inc holds $4,343,317 across 8 Drug Manufacturers - General names. GILD ranks #6 (6.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
984 | $1,180,239 | |
| 2 | JNJ |
Johnson & Johnson
|
3,798 | $964,578 | |
| 3 | AMGN |
Amgen Inc
|
1,994 | $722,067 | |
| 4 | ABBV |
AbbVie Inc.
|
1,610 | $405,140 | |
| 5 | BMY |
Bristol Myers Squibb Co
|
5,713 | $329,183 | |
| 6 | GILD |
Gilead Sciences, Inc.
This page
|
2,050 | $258,997 | |
| 7 | PFE |
Pfizer Inc
|
10,372 | $249,757 | |
| 8 | MRK |
Merck & Co., Inc.
|
1,816 | $233,356 |
All Filings in GILD
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $258,997 | 2,050 | Shares | Sole | 2026-07-27 | |
| 2026-03-31 | $285,708 | 2,050 | Shares | Sole | 2026-04-21 | |
| 2025-12-31 | $251,617 | 2,050 | Shares | Sole | 2026-01-23 | |
| 2025-09-30 | $227,550 | 2,050 | Shares | Sole | 2025-10-31 | |
| 2025-06-30 | $227,283 | 2,050 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | $229,702 | 2,050 | Shares | Sole | 2025-04-28 | |
| 2021-03-31 | $220,452 | 3,411 | Shares | Sole | 2021-05-05 | |
| 2020-09-30 | $225,019 | 3,561 | Shares | Sole | 2020-10-19 | |
| 2020-06-30 | $254,748 | 3,311 | Shares | Sole | 2020-08-04 | |
| No filing history on record for this holder in this stock. | ||||||